Hemerion Therapeutics
↗Villeneuve d'Ascq, France
Hemerion Therapeutics is a French clinical-stage biotech company founded in 2020 that develops innovative photodynamic therapy (PDT) technologies for cancer treatment. The company is built on more than 10 years of academic research conducted within an INSERM laboratory in partnership with the University of Lille and Lille University Hospital. Hemerion's lead therapeutic platform combines a photosensitizing drug (Pentalafen®) with an illumination medical device (Heliance® Solution), designed for intraoperative use following tumor resection. The Pentalafen®/Heliance® combination therapy is currently being developed as a first-in-class treatment for glioblastoma, the most aggressive form of primary brain cancer, with expansion into other cancer indications planned.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:€12.05M
Investors:CapTech Santé fund (€1.5M in Series A), Nord France Amorçage fund (€1M in Series A), Fira Nord-Est 2 fund/Finovam Gestion (€1M in Series A), Capital Cell crowdfunding platform (€0.8M from ~265 private investors), European FEDER fund (€1.5M), Bpifrance (€2M - €1.5M recoverable advance + €0.5M grants), Business angels, Private investors
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2 clinical trial (HTX-GBM-01)
Modalities:Drug-device combination, Photodynamic therapy, Photosensitizing agents
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:INSERM (exclusive license holder, ongoing research partnership), University of Lille (academic collaboration, research partnership), Lille University Hospital (clinical trial partnership, joint research), University of Pittsburgh Medical Center (Phase 1/2 clinical trial site), SATT Nord (technology transfer partner, exclusive license grantor)
COMPETITION
Position:Niche Player - First-in-class photodynamic therapy for glioblastoma in clinical development
Competitors:MEDPNC (Israeli startup - personalized combination cancer therapies), Other glioblastoma treatment companies (e.g., standard chemotherapy providers like Stupp protocol users), Other photodynamic therapy developers (not specifically named in available data)
LEADERSHIP
Key Executives:
Maximilien Vermandel - Co-Founder and Chief Executive Officer
Clément Dupont - Co-Founder and Chief Technology Officer
Michel Andraud - Chief Financial Officer
Marie-Edith Bonneterre - Medical Strategy Lead
Fabienne Lecomte - Regulatory and Clinical Operations Lead
Antoine Mequignon - Clinical Development Director
Mélanie Rose - Head of Research
Everardo Saad - Medical Director
Scientific Founders:Serge Mordon (INSERM researcher - co-founder), Nicolas Reyns (Neurosurgeon - co-founder)
Board Members:Costas Hadjipanayis (Scientific Advisory Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Hemerion Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.